Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trimeris (TRMS) -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (33)	1/8/1998 2:15:00 PM
From: mike head	Respond to of 108

Pseudo B. What a great overall report! Thank you.

To: Pseudo Biologist who wrote (33)	1/21/1998 3:02:00 PM
From: Elroy Jetson	Read Replies (1) \| Respond to of 108

Did you read the recent press release announcing the expansion of the T-20 trials? This continues to look like the most promising treatment for HIV protease inhibitor failure. Sales of most protease inhibitors are running at $350 million per year. If T-20 is similar, that's sales of $35 per share.